Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly – a randomised, double-blinded trial

Iwanuk, Nayeli; Nolte, Ingo; Wall, Leona; Sehn, Maximiliane; Raue, Jonathan; Pilgram, Anna; Rumstedt, Katja; Bach, Jan-Peter

doi:10.1186/s12917-019-1980-z

Cited by 9 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This presumably results from reduced filling pressure, which is caused by a reduced pre- and afterload due to the inotropic and vasodilative effects of pimobendan [ 24 ]. Furthermore, the effect was absent at long-term follow-up at day 180, which again is in accordance with the aforementioned studies [ 8 , 21 ]. Weekly variability in NT-proBNP plasma values within individuals could be a possible explanation for the lack of significant long-term results [ 25 ].…”

Section: Discussionsupporting

confidence: 92%

“…Included in the answer to question number one, whether pimobendan has a positive effect on the collected data, cardiac biomarkers were the most sensitive diagnostic tools mentioned as reflecting the influence and impact of treatment. At day 90 of treatment with pimobendan, significantly lower pre-exercise NT-proBNP concentrations were apparent, which agrees with the findings of previous studies [ 8 , 21 ]. The main stimulus for secretion of natriuretic peptides is increased wall stress of the left ventricle [ 22 ].…”

Section: Discussionsupporting

confidence: 92%

“…All dogs included in the study underwent an SSET on a motorised treadmill (“quasar”, h/p/cosmos sports and medical GmbH, Nussdorf-Traunstein, Germany) as recently established by Wall et al and utilised in the predecessor study by Iwanuk et al [ 8 , 9 , 19 ]. Before starting the examinations for the study, dogs had been accustomed to the treadmill and the speed of the treadmill had been slowly increased to their respective comfort speed.…”

Section: Methodsmentioning

confidence: 99%

“…While there have been negative reports regarding the effect of pimobendan in dogs with preclinical DMVD [ 6 , 7 ] , a recent study by our group showed some promising results concerning the effect on cardiac biomarkers and quality of life of dogs as assessed by the owners [ 8 , 9 ]. In this previous study, dogs of stage ACVIM B1 were randomly allocated to either group A (receiving pimobendan) or group B (receiving placebo), and underwent echocardiography, standardised submaximal exercise testing (SSET) and investigation of cardiac biomarkers.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Pimobendan is a widely used medication for the treatment of dogs with congestive heart failure (CHF) and preclinical degenerative mitral valve disease (DMVD) with cardiomegaly. The benefit of a treatment in dogs with preclinical DMVD but without cardiomegaly has not yet been elucidated. Some positive effects concerning life quality and a decrease in cardiac biomarkers could be verified. This study aimed to further investigate these results using a placebo-controlled double-blinded crossover design. Out of a total of 15 dogs, eight were allocated to sequence-group AB, in which dogs received pimobendan (A) during the first treatment period and placebo (B) during the second period. Accordingly, sequence-group BA was treated first with placebo followed by pimobendan. Each treatment period lasted six months and included a baseline investigation and follow-ups after 90 and 180 days. The investigations included a questionnaire completed by the owners, echocardiographic examination, and measurements of NT-proBNP, cTnI and lactate before and after a standardised submaximal exercise test. Results NT-proBNP values decreased significantly during the treatment period with pimobendan, and the post-exercise increase was attenuated at day 180. No significant treatment effects could be verified for cTnI and lactate, neither pre- nor post-exercise. Left ventricular size decreased under treatment, whereas no significant changes in left atrial size were detected. The owners described their dogs under treatment with pimobendan as being more active at day 90 (11/15) and day 180 (12/15). Those animals treated with placebo were described as being more active at day 90 (2/15) and day 180 (5/15). Conclusions Pimobendan had reducing effects on the concentrations of pre- and post-exercise cardiac biomarkers and the size of the left ventricle in dogs with DMVD ACVIM B1. Exercise testing in addition to an assessment of cardiac biomarkers might improve the decision when to initiate pimobendan treatment in dogs with DMVD.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Dogs with severe systemic diseases or orthopedic symptoms and those unwilling to run on the treadmill were excluded from the study. In addition to the examinations described below, cardiac biomarker testing was also performed in conjunction with exercise testing in the dogs participating in the study [24].…”

Section: Methodsmentioning

confidence: 99%

Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly

et al. 2019

Self Cite

View full text Add to dashboard Cite

Pimobendan has gained enormous importance in the treatment of mitral valve disease in dogs. The current consensus statement of the American College of Veterinary Internal Medicine (ACVIM) recommends a treatment for dogs with symptomatic disease and dogs with asymptomatic disease with radiographic and echocardiographic signs of cardiomegaly. To investigate whether these dogs also benefit from a therapy with pimobendan, 21 dogs with mitral valve disease ACVIM B1 underwent a standardized submaximal exercise test on a treadmill. In this double-blinded and randomized study, the animals were divided into two groups, one receiving pimobendan and the other a placebo. At the first visit and at every follow-up appointment (at days 90 and 180), heart rate during the complete exercise test and lactate before and after running were measured. In addition to this, a questionnaire was completed by the dogs’ owners and all dogs were given an echocardiographic examination to detect any changes and to observe if the disease had progressed. Due to the diagnosis of leishmaniosis, one dog in the pimobendan group was retrospectively removed from the study so that 20 dogs were included for statistical analysis. No differences were observed at any time between the pimobendan-group and the placebo-group regarding heart rate. At day 180, the increase in lactate after exercise was significantly lower than in the placebo-group. The increase in the pimobendan-group at day 180 was lower than at day 90. Most of the dog owners from the pimobendan-group declared that their dogs were more active at day 90 (6/10) and at day 180 (8/10), while most dog owners from the placebo-group observed no changes regarding activity at day 90 (8/10) and day 180 (6/10). It can be concluded that the results of this study indicate that some dogs with mitral valve disease ACVIM B1 might benefit from a therapy with pimobendan.

show abstract

Use of cardiac troponin I, lactic acid, procalcitonin, and serum complement C3 as prognostic indicators in patients with sepsis

Chen,

Liu,

Tang

et al. 2023

Medicine

View full text Add to dashboard Cite

Sepsis is a heterogeneous syndrome caused by the immune response to severe infection. This study aimed to investigate the value of cardiac troponin I, lactic acid, procalcitonin, and serum complement C3 levels for predicting death in patients with sepsis. Patients with sepsis who were hospitalized in the Department of Critical Care Medicine at our hospital between June 2017 and October 2022 were included in this retrospective study and divided into a survival group and a death group according to their survival status after 28 days. The Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, and levels of cardiac troponin I, lactic acid, procalcitonin, and serum complement C3 were measured. A total of 516 patients were included in the analysis. Multivariable analysis showed that the APACHE II score (P < .001), SOFA score (P < .001), and cardiac troponin I (P < .001), lactic acid (P = .002), procalcitonin (P < .001), and serum complement C3 (P = .01) levels were independent predictors of sepsis death. The area under the receiver operating characteristic curve (AUC) was 0.882 (95% CI: 0.794–0.941) in patients with sepsis predicted using a combination of cardiac troponin I, lactic acid, procalcitonin, and serum complement C3 levels, which was better than the predictive value of cardiac troponin I (AUC: 0.734, 95% CI: 0.628–0.824), lactic acid (AUC: 0.686, 95% CI: 0.576–0.781), procalcitonin (AUC: 0.727, 95% CI: 0.620–0.817), or serum complement C3 (AUC: 0.684, 95% CI: 0.575–0.780) alone. Cardiac troponin I, lactic acid, and procalcitonin levels are independent predictors of death, whereas serum complement C3 protects against death in patients with sepsis. The combination of cardiac troponin I, lactic acid, procalcitonin, and serum complement C3 levels has a better predictive value for death than any single measure alone in patients with sepsis.

show abstract

Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly – a randomised, double-blinded trial

Cited by 9 publications

References 37 publications

The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study

The effect of treatment with pimobendan in dogs with preclinical mitral valve disease – a placebo-controlled double-blinded crossover study

Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly

Use of cardiac troponin I, lactic acid, procalcitonin, and serum complement C3 as prognostic indicators in patients with sepsis

Contact Info

Product

Resources

About